About Nobelpharma America, LLC

Nobelpharma America, LLC is a U.S subsidiary of a purpose-driven Japanese pharmaceutical company which is seeking to enter the U.S. market to bring drugs and medical devices to individuals whose conditions are often overlooked because of the small number of patients affected. Our “patients first” approach is to develop drugs and medical devices that target medical conditions with limited or no other treatment options, regardless of market size.

We will continue to further evolve by developing First-In-Class & Best-In-Class drugs and launch products in more regions, such as the United States and Europe.

• Facial Angiofibroma Associated with Tuberous Sclerosis Complex (TSC), is Focus of New Disease Education Website Launched by Nobelpharma America (January 2023)
• HYFTOR^TM (sirolimus topical gel) 0.2%, Now Available in the U.S (August 30, 2022)
• FDA approves Nobelpharma’s HYFTOR^TM (April 04, 2022)
• The TSC Alliance is a resource for those affected by TSC and recently launched a support tool, the TSC Navigator (November 1, 2021)
• Nobelpharma introduced by Nature Portfolio (October 2021) *Nobelpharma products have not been approved or deemed safe and effective by the U.S. FDA and are not available for commercial sale in the U.S.
• Nobelpharma America Announces Presence at 2021 Society for Pediatric Dermatology Annual Meeting (July 6, 2021)
• Nobelpharma America Recognized by the TSC Alliance for Commitment to TSC Community (June 22, 2021)
• Tuberous Sclerosis Alliance and Nobelpharma to Celebrate Rare Disease Day with New Partnership (May 18, 2021)
• Nobelpharma America introduced by Washington Business Journal (September 1, 2020)